Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPL389 dose-ranging study in moderate to severe atopic dermatitis
NL-OMON48764Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adriforant in atopic dermatitis (AD) (5 arms), sponsored by Novartis. Primary endpoint: IGA response at 16 weeks. Started Apr 2019; status: recruiting.
02
Drugs
adriforant
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON48764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48764.